TALZENNA (talazoparib)

TALZENNA (talazoparib)

SELF ADMINISTRATION - ORAL

Indications for Prior Authorizations: 

• Indicated in adult patients with deleterious or suspected deleterious germline BReast CAncer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.

Must meet the following criteria for coverage: 

• Patient is of 18 years of age or older, AND
• Prescribed by or in consultation with an oncologist, AND
• Patient has locally-advanced or metastatic breast cancer, AND
• Patient has germline BRCA mutation-positive disease, AND
• Patient has human epidermal growth factor receptor 2 (HER2)-negative breast cancer

Dosing:

• 1 mg taken orally once daily
• 0.25 mg capsule is available for dose reduction

Approval: 

1 year